StockNews.com Initiates Coverage on Ayala Pharmaceuticals (NASDAQ:ADXS)

StockNews.com began coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a research note released on Wednesday. The firm issued a sell rating on the stock.

Ayala Pharmaceuticals Stock Performance

Shares of ADXS opened at $0.02 on Wednesday. The firm has a market cap of $852,660.00, a P/E ratio of 0.00 and a beta of 1.56. Ayala Pharmaceuticals has a 12 month low of $0.00 and a 12 month high of $1.49. The stock’s 50 day moving average is $0.15 and its two-hundred day moving average is $0.44.

Ayala Pharmaceuticals Company Profile

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.